postoperative thoracic pain management
Conditions
Interventions
Continuous paravertebral nerve block with bupivacaine:Continuous infusion of bupivacaine via deep fascial catheter placement in the serratus anterior muscle after surgery
"Liposomal bupivacaine single-shot paravertebral nerve block.":Deep fascial injection of 40 ml of 0.25% liposomal bupivacaine into the serratus anterior muscle.
Sponsors
Chengdu Second People’s Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Participants who fully understand the purpose, nature, methods, and potential adverse reactions of this study, voluntarily agree to participate in this trial, and sign an informed consent form; individuals scheduled to undergo unilateral thoracoscopic chest surgery under general anesthesia between July 2024 and August 2025 (such as pulmonary lobectomy, wedge resection, or segmentectomy). 2) Anticipated surgery duration between 1 hour to 3 hours (including critical thresholds), with an expected total surgical incision length = 6 cm. 3) Subjects classified under American Society of Anesthesiologists (ASA) physical status classification I-II; aged between 18 to 65 years old (inclusive), of any gender; body mass index (BMI) between 18.0 to 30 kg/m2 (inclusive), with male participants weighing no less than 50 kg and female participants weighing no less than 45 kg. 4) Capable of good communication with researchers, understanding the requirements of this trial, and the use of the Visual Analog Scale (VAS) pain assessment tool.
Exclusion criteria
Exclusion criteria: 1) History of allergy or contraindication to amide local anesthetics such as bupivacaine, or any excipients in liposomal bupivacaine. 2) Injection site or systemic infection; severe coagulation disorders; history of opioid misuse; chronic pain conditions; cognitive impairment. 3) Severe systemic diseases affecting cardiovascular, hepatic, renal, respiratory, hematologic, lymphatic, endocrine, immune, neurological, gastrointestinal systems, etc. 4) Within the past year, history of any of the following conditions: congestive heart failure (NYHA class III or IV), angina pectoris, myocardial infarction, pulmonary heart disease, severe arrhythmias, uncontrolled asthma (=1 acute attacks per week), or coronary artery bypass surgery. 5) History of lung surgery and/or other ipsilateral thoracic surgeries, or plans for concurrent surgical procedures during the study period (such as bilateral thoracoscopic surgery); history of chronic pain or ongoing analgesic therapy before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative Recovery Quality Scale at 24 hours and 48 hours; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scale (VAS) pain scores at 24 hours and 48 hours postoperatively;Pulmonary function testing;Intraoperative and postoperative total opioid consumption;Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactMingyue Zhang
Chengdu Second People’s Hospital
Outcome results
None listed